Leukemia--Acute Myeloid (Myelogenous)

+ -Text Size

Treating Leukemia - Acute Myeloid (AML) TOPICS

Treatment response rates for acute myeloid leukemia

For most types of acute myeloid leukemia

Induction is successful in about 65% of all acute myeloid leukemia (AML) patients who get standard induction chemotherapy (chemo) with daunorubicin and cytarabine. The actual chance of remission depends to a large part on a person’s specific prognostic factors, such as age or the presence of certain gene or chromosome changes.

If remission is achieved, patients may then have more chemo (consolidation). A common regimen is 3 or 4 cycles of high dose ara-C (HiDAC). Up to half of patients that get this go into long-term remission (and may be cured). But this number is also affected by prognostic factors, such as age and whether the leukemia cells have certain gene or chromosome changes. Using an allogeneic stem cell transplant as consolidation has a higher success rate but also has a higher risk of death as a complication.

Older patients generally don’t do as well as those younger than 60. They have trouble tolerating intensive treatment and often have chromosome changes in their leukemia cells that are linked to a poorer outlook.

For acute promyelocytic leukemia (APL)

More than 90% of patients go into remission with standard induction treatment. With consolidation and maintenance, about 70% to 90% of patients with APL are successfully treated long-term.

Last Medical Review: 07/24/2013
Last Revised: 02/07/2014